Hearing loss is the most common sensory impairment, affecting over 1.57 billion people globally and significantly impacting quality of life. Recognized by the WHO as a research priority, it incurred estimated global economic costs exceeding $981 billion in 2019. Currently, there are no therapies that can restore or halt sensorineural hearing loss (SNHL); treatment is limited to hearing aids or cochlear implants, depending on severity.

However, in early 2024, phase 1/2 trials demonstrated the first successful restoration of hearing in individuals with DFNB9-related deafness using gene therapy, marking a breakthrough in molecular interventions. These advances stem from growing insights into cochlear physiology and the 140+ genes implicated in hearing loss—each offering potential therapeutic targets. Effective treatments must consider the underlying cause, affected cell types, degree of hearing loss, and whether the goal is prevention or restoration.

Beyond therapies, there's an urgent need for objective biomarkers to assess therapeutic impact and for non-invasive delivery methods that preserve inner ear integrity.

Our Scientific Research Network aims to foster national and international collaboration on innovative therapies to cure hearing loss, moving beyond rehabilitation. This includes developing objective biomarkers and creating a shared platform for scientific exchange, funding acquisition, and researcher training and mobility.